Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues.
Biomarkers
Cancer
Exosomal lncRNAs
Exosomes
Intercellular and intracellular communication
Journal
Non-coding RNA research
ISSN: 2468-0540
Titre abrégé: Noncoding RNA Res
Pays: Netherlands
ID NLM: 101688191
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
27
11
2023
revised:
20
03
2024
accepted:
29
03
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
15
4
2024
Statut:
epublish
Résumé
In the intricate field of cancer biology, researchers are increasingly intrigued by the emerging role of exosomal long non-coding RNAs (lncRNAs) due to their multifaceted interactions, complex modulation mechanisms, and potential therapeutic applications. These exosomal lncRNAs, carried within extracellular vesicles, play a vital partin tumorigenesis and disease progression by facilitating communication networks between tumor cells and their local microenvironment, making them an ideal candidates for use in a liquid biopsy approach. However, exosomal lncRNAs remain an understudied area, especially in cancer biology. Therefore this review aims to comprehensively explore the dynamic interplay between exosomal lncRNAs and various cellular components, including interactions with tumor-stroma, immune modulation, and drug resistance mechanisms. Understanding the regulatory functions of exosomal lncRNAs in these processes can potentially unveil novel diagnostic markers and therapeutic targets for cancer. Additionally, the emergence of RNA-based therapeutics presents exciting opportunities for targeting exosomal lncRNAs, offering innovative strategies to combat cancer progression and improve treatment outcomes. Thus, this review provides insights into the current understanding of exosomal lncRNAs in cancer biology, highlighting their crucial roles, regulatory mechanisms, and the evolving landscape of therapeutic interventions. Furthermore, we have also discussed the advantage of exosomes as therapeutic carriers of lncRNAs for the development of personalized targeted therapy for cancer patients.
Identifiants
pubmed: 38616862
doi: 10.1016/j.ncrna.2024.03.014
pii: S2468-0540(24)00082-9
pmc: PMC11015109
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
887-900Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
All the authors declare no conflict of interest.